Kairos Pharma, Ltd., a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer. The phase I trial is…
eTurboNews ບົດຄວາມແມ່ນສໍາລັບຜູ້ຈອງເທົ່ານັ້ນ. ການສະໝັກໃຊ້ແມ່ນ ອອນໄລນ໌.
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສະມາຊິກເຂົ້າສູ່ລະບົບທີ່ນີ້ ຄລິກທີ່ນີ້ເພື່ອສະໝັກຟຣີ
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- , a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer, today announced that its activated T cell therapy, KROS 201, has received FDA approval to proceed with a Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer.
- ການສະໝັກໃຊ້ແມ່ນບໍ່ເສຍຄ່າ.
- The phase I trial is….
